Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva (NYSE: TEVA) received a ratings upgrade and outlook revisions on Dec 24, 2025: S&P raised the long-term rating to BB+ (from BB) with a stable outlook, while Moody's affirmed B1a and moved the outlook to positive from stable.
S&P cited adjusted leverage of 4.4x as of Sept 30, 2025 and expects leverage to drop below 4.25x in coming quarters; Moody's expects leverage toward 3.5x within 12–18 months. Both agencies pointed to deleveraging, returning revenue growth, branded-medicine momentum, biosimilar launches, and strong liquidity as drivers supporting higher ratings.
Alvotech (NASDAQ: ALVO) and Teva (NYSE: TEVA) announced a settlement and license with Regeneron that sets a U.S. market entry date for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), in the fourth quarter of 2026, or earlier under specified circumstances, subject to FDA approval.
AVT06 has already received marketing approvals in the United Kingdom, Japan, and the 30 EEA countries. A January 2024 confirmatory study met its primary endpoint, showing high similarity to Eylea® for neovascular AMD.
Teva (NYSE:TEVA) will release its fourth quarter 2025 financial results on Wednesday, January 28, 2026 at 7:00 a.m. ET.
Teva will host a conference call and live webcast the same day at 8:00 a.m. ET. Investors must register in advance to obtain local or toll-free dial-in numbers and a personal PIN. A live webcast will be available at https://ir.tevapharm.com/Events-and-Presentations, and a replay will be posted within 24 hours on the same site.
Teva (NYSE: TEVA) posted its Q4 2025 Aide Memoire on the company's Investors page to help investors ahead of fourth-quarter results.
The Aide Memoire compiles previously disclosed public information, prior results, management commentary and select independent data. Q4 2025 results are scheduled for Wednesday, January 28, 2026 at 7:00 AM ET, followed by a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) submitted a New Drug Application (NDA) to the FDA on December 9, 2025 for olanzapine extended-release injectable suspension (TEV-'749), an investigational once-monthly subcutaneous long-acting injectable (LAI) for adults with schizophrenia.
The NDA is supported by Phase 3 SOLARIS trial data, including Week 56 results that the company says met efficacy and safety endpoints and showed a profile consistent with oral olanzapine. The formulation uses SteadyTeq copolymer technology, proprietary to Medincell. Olanzapine LAI is not approved by any regulatory authority at this time.
Teva (NYSE: TEVA) announced that the European Commission granted marketing authorizations on Nov 25, 2025 for two denosumab biosimilars: PONLIMSI (biosimilar to Prolia) and DEGEVMA (biosimilar to Xgeva).
The approvals follow positive CHMP opinions and allow Teva to launch both products in key European markets in the coming months. Teva frames the authorizations as a milestone for its biosimilars portfolio and part of its Pivot to Growth strategy to broaden patient access to bone‑health biologics across Europe.
Teva (NYSE: TEVA) announced that Richard Francis, president and CEO, and other executive management will present at three investor conferences in early December 2025.
Schedule: Evercore Healthcare Conference on Dec 3, 2025 at 8:20 AM ET; Piper Sandler Healthcare Conference on Dec 3, 2025 at 11:00 AM ET; and Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 10:30 AM ET. Live webcasts will be available via Teva’s Investor Relations website and archived within 24 hours after each live presentation.
Teva (NYSE:TEVA) launched Teva Rise, a global open innovation platform on Nov 19, 2025 to connect startups and tech companies with Teva business units across R&D, manufacturing, supply chain and commercial functions.
The program issues an open call for solutions to seven real-world challenges (human-predictive platforms, AI clinical-trial protocol design, long-acting injectable patient experience, tender value optimization, asset predictive maintenance, product quality & risk prediction, and resource allocation intelligence) and may pilot selected startups across Teva’s global ecosystem.
Teva said it will channel tens of millions of dollars into adopting these innovations as part of its Pivot to Growth strategy.
Teva (NYSE: TEVA) announced interim real-world results from Part B of the IMPACT-TD Registry (Nov 7, 2025) showing patient-reported benefits after three months on AUSTEDO or AUSTEDO XR for tardive dyskinesia (TD).
In 27 adults, participants reported meaningful improvements in speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). The Abnormal Involuntary Movement Scale (AIMS) total motor score fell by a mean of -2.9. Among those taking concomitant mental health meds, 85% reported stable or improved mental health.
Teva (NYSE: TEVA) reported Q3 2025 revenues of $4.5 billion, marking the 11th consecutive quarter of growth. Key innovative brands grew 33% YoY in local currency to $830 million, led by AUSTEDO $618M (+38% LC), and Teva raised AUSTEDO's 2025 outlook to $2,050M–$2,150M. Q3 non-GAAP operating margin was 28.9% (+86 bps YoY), with a target of 30% by 2027. Q3 GAAP EPS was $0.37 and non-GAAP EPS $0.78. Free cash flow was $515M. Updated 2025 outlook: revenues $16.8B–$17.0B, non-GAAP EPS $2.55–$2.65.